(Q36821988)

16 August 2017

1 reference

title

Mechanisms of action of etanercept in psoriasis (English)

1 reference

16 August 2017

Jennifer K Tan

1

1 reference

16 August 2017

Abhishek Aphale

2

1 reference

16 August 2017

Rama Malaviya

3

1 reference

16 August 2017

Yvonne Sun

4

1 reference

16 August 2017

Alice B Gottlieb

5

1 reference

16 August 2017

publication date

1 May 2007

1 reference

The journal of investigative dermatology. Symposium proceedings

16 August 2017

published in

1 reference

16 August 2017

volume

12

1 reference

16 August 2017

issue

1

1 reference

16 August 2017

page(s)

38-45

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.jidsymp.5650037

16 August 2017

exact match

0 references

cites work

Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

An endotoxin-induced serum factor that causes necrosis of tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

Psoriasis--epidemiology and clinical spectrum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

PUVA-induced lymphocyte apoptosis: mechanism of action in psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

1 reference

7 January 2021

TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

The immunologic basis for the treatment of psoriasis with new biologic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

Etanercept as monotherapy in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

Activators and target genes of Rel/NF-kappaB transcription factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

The NF-kappaB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

Role of NF-kappaB activity in apoptotic response of keratinocytes mediated by interferon-gamma, tumor necrosis factor-alpha, and tumor-necrosis-factor-related apoptosis-inducing ligand

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

The promise and challenge of new biological treatments for psoriasis: how do they impact quality of life?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JIDSYMP.5650037

7 January 2021

10.1038/SJ.JIDSYMP.5650037

Identifiers

DOI

1 reference

Dimensions Publication ID

16 August 2017

1013181005

0 references

1 reference